Letters Contralateral mastectomy and BRCA1 and BRCA2

Threshold for genetic testing in women with breast cancer needs to be determined

BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1863 (Published 06 March 2014) Cite this as: BMJ 2014;348:g1863
  1. Narendra Nath Basu, oncoplastic breast surgeon1,
  2. Lester Barr, oncoplastic breast surgeon2,
  3. D Gareth Evans, professor of medical genetics and cancer epidemiology3,
  4. Gary L Ross, plastic and reconstructive surgeon and honorary senior lecturer, University of Manchester3
  1. 1Queen Elizabeth Hospital, Birmingham, UK
  2. 2University Hospital of South Manchester, Manchester, UK
  3. 3St Mary’s Hospital, Manchester, UK
  1. naren_basu{at}hotmail.com

US surveillance data describe a 150% increase in contralateral mastectomy in the past decade, so Metcalfe and colleagues’ study of survival in BRCA1 and BRCA2 mutation carriers undergoing contralateral mastectomy after breast cancer is timely.1 2 Since Angelina Jolie’s risk reducing surgery, clinicians often have to counsel patients asking for such procedures.

This study’s findings on survival benefit are similar to our own. …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe